---
layout: post
title: "Submitting Documents Using Real-World Data and Real-World Evidence to the Food and Drug Administration for Drug and Biological Products; Guidance for Industry; Availability"
date: 2026-02-05 19:00:39 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-19494
original_published: 2022-09-09 00:00:00 +0000
significance: 8.00
---

# Submitting Documents Using Real-World Data and Real-World Evidence to the Food and Drug Administration for Drug and Biological Products; Guidance for Industry; Availability

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** September 09, 2022 00:00 UTC
**Document Number:** 2022-19494

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products." To facilitate FDA's internal tracking of submissions to the Agency that include real-world data (RWD) and real- world evidence (RWE), this guidance encourages sponsors and applicants to identify in their submission cover letters certain uses of RWD/RWE. This guidance does not address FDA's substantive review of the RWD/RWE submitted as part of the Agency's standard review process. This guidance finalizes the draft guidance entitled "Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics" issued on May 9, 2019.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/09/09/2022-19494/submitting-documents-using-real-world-data-and-real-world-evidence-to-the-food-and-drug)
- API: https://www.federalregister.gov/api/v1/documents/2022-19494

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
